Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, Poulton I, Baker M, Mitton C, Baines A, Meier A, Schmidt G, Harrop R, Protheroe A, MacPherson R, Kennish S, Morgan S, Vigano S, Romero PJ, Evans T, Catto J, Hamdy F, Hill AVS, Redchenko I. Cappuccini F, et al. Among authors: redchenko i. J Immunother Cancer. 2020 Jun;8(1):e000928. doi: 10.1136/jitc-2020-000928. J Immunother Cancer. 2020. PMID: 32591433 Free PMC article. Clinical Trial.
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J, Chan HF, Noblecourt L, Ramirez-Valdez RA, Pereira-Almeida V, Zhou Y, Pollock E, Cappuccini F, Redchenko I, Hill AV, Leung CSK, Van den Eynde BJ. McAuliffe J, et al. Among authors: redchenko i. J Immunother Cancer. 2021 Sep;9(9):e003218. doi: 10.1136/jitc-2021-003218. J Immunother Cancer. 2021. PMID: 34479921 Free PMC article.
Monitoring of human immunological responses to vaccinia virus.
Harrop R, Ryan MG, Golding H, Redchenko I, Carroll MW. Harrop R, et al. Among authors: redchenko i. Methods Mol Biol. 2004;269:243-66. doi: 10.1385/1-59259-789-0:243. Methods Mol Biol. 2004. PMID: 15114020 Review.
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, Carroll MW. Harrop R, et al. Among authors: redchenko i. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3416-24. doi: 10.1158/1078-0432.CCR-05-2732. Clin Cancer Res. 2006. PMID: 16740766 Clinical Trial.
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, Hawkins RE. Harrop R, et al. Among authors: redchenko i. Cancer Immunol Immunother. 2008 Jul;57(7):977-86. doi: 10.1007/s00262-007-0428-7. Cancer Immunol Immunother. 2008. PMID: 18060404 Clinical Trial.
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, Wassan H, Habib N, Anthoney A. Harrop R, et al. Among authors: redchenko i. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4487-94. doi: 10.1158/1078-0432.CCR-07-0704. Clin Cancer Res. 2007. PMID: 17671134 Clinical Trial.
22 results